EP3630300A1 - Préparation cosmétique ou dermatologique contenant un extrait d'oeuf de poisson aqueux et un extrait d'oeuf de poisson lipophile - Google Patents

Préparation cosmétique ou dermatologique contenant un extrait d'oeuf de poisson aqueux et un extrait d'oeuf de poisson lipophile

Info

Publication number
EP3630300A1
EP3630300A1 EP18726089.8A EP18726089A EP3630300A1 EP 3630300 A1 EP3630300 A1 EP 3630300A1 EP 18726089 A EP18726089 A EP 18726089A EP 3630300 A1 EP3630300 A1 EP 3630300A1
Authority
EP
European Patent Office
Prior art keywords
aqueous
cosmetic
fish extract
fish
extract
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP18726089.8A
Other languages
German (de)
English (en)
Inventor
Daniel Stangl
Bernhard DUDLER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prairie Group AG
Original Assignee
Prairie Group AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prairie Group AG filed Critical Prairie Group AG
Publication of EP3630300A1 publication Critical patent/EP3630300A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/981—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of mammals or bird
    • A61K8/982—Reproductive organs; Embryos, Eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/46—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing sulfur
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
    • A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/35—Extraction with lipophilic solvents, e.g. Hexane or petrol ether
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
    • A61K2800/59—Mixtures
    • A61K2800/591—Mixtures of compounds not provided for by any of the codes A61K2800/592 - A61K2800/596

Definitions

  • Cosmetic or dermatological preparation containing an aqueous and a lipophilic fish extract containing an aqueous and a lipophilic fish extract
  • the present invention relates to a cosmetic or dermatological preparation comprising an aqueous and a lipophilic fish extract.
  • a common nuisance to many women and men is that the skin, especially the facial skin, loses volume and firmness with age. As a result, the facial contours may change visibly. One result is the undesirable wrinkling.
  • the subcutaneous tissue forms the deepest skin layer. Depending on the body position, the subcutaneous tissue has a different thickness. So this is especially thin on the forehead, while it is much thicker on the buttocks. Overall, the subcutis accounts for 15% to 30% of body weight.
  • the subcutis is composed of connective tissue and fat cells.
  • the latter serve as reserve cells to store excess nutrients that are not needed in the organism.
  • fats such as triglycerides
  • these reserve cells or fat cells are called adipocytes.
  • the formation of adipocytes occurs to a large extent in only three stages of human life: the last three months of pregnancy, the first year of birth and the beginning of adolescence.
  • Precursor cells of the adipocytes are lost or their activity is lost.
  • the logical consequence here too is wrinkling, since the firmness of the skin is reduced.
  • One of the adipocyte's abilities is the incorporation of triglycerides, which causes skin layers to become cushioned. If many triglycerides are stored, the padded skin is more relaxed. Depending on the body region, this is more or less desirable.
  • the subcutaneous tissue in the face is characterized by a comparatively small layer thickness.
  • a particularly effective incorporation of triglycerides can therefore lead to an effective padding of the skin in this body area.
  • upholstery is accompanied by a visible reduction in the depth of the fold.
  • the outermost human skin layer is described as an epidermis, which is the only keratinizing squamous epithelium of the human body.
  • this epithelium fulfills various protective functions: Among other things, it serves as a mechanical protection, which is primarily generated by the multi-layered structure.
  • the epidermis of the skin must have sufficient tear resistance and must not detach from the underlying connective tissue.
  • the basal lamina Between the epithelium and the connective tissue is the basal membrane, whose uppermost layer is called the basal lamina.
  • the basal lamina has a thickness of about 20 nm, the entire basement membrane has a thickness of about 1-2 ⁇ .
  • the basal lamina is immediately adjacent to the epithelial cell and is further subdivided into the lamina rara and the lamina densa according to its electron permeability.
  • the lamina rara and underlying lamina densa consist mainly of the type IV collagen proteins and laminin, which is cross-linked with the extracellular domains of the epithelial cell membrane integrins, as well as entactin (nidogen) and proteoglycans such as pearlcan.
  • other proteins may be associated with the addressed matrix components.
  • laminins are collagen-like glycoproteins with a molecular weight in the range of 400 to 900 kDa.
  • laminin consists of 3 structural components called o, ⁇ and ⁇ chains.
  • the molecule has 4 arms, of which 3 with other laminin molecules can bind. The remaining, longer arm binds to cell surfaces.
  • laminin is of great importance for the cohesion of the tissue, the so-called cell adhesion.
  • laminin carries not only for cell attachment and differentiation but also to
  • Another object of the present invention is thus cosmetic or
  • laminin-5 dermatological preparations or cosmetic agents which promote the formation of laminin.
  • the formation of laminin-5 should be promoted, which forms a network with collagens and thus affects the extensibility and elasticity of the skin.
  • the subject of the present invention is a cosmetic or dermatological preparation containing
  • I an aqueous fish extract (I), characterized in that the aqueous
  • the fish eggs are suspended in an extraction mixture containing an oil phase and an aqueous phase,
  • the fish eggs are suspended in an extraction mixture containing an oil phase and an aqueous phase,
  • the oil phase obtained in point c2) provides the lipophilic fish extract (II) according to the invention.
  • the present invention also relates to the cosmetic use of the cosmetic preparation a) according to the invention for upholstering the skin;
  • laminin-5 subunit ß particularly preferred.
  • Normal conditions performed.
  • the term "normal conditions” means 20 ° C, 1013 hPa and a relative humidity of 50%.
  • a cosmetic or dermatological preparation containing an aqueous fish extract and a lipophilic fish extract, the expression of laminin, especially of laminin-5 and in particular of laminin-5 subunit ⁇ .
  • the combination of the two different fish extracts shows a surprising synergism.
  • application to the skin results in more laminin, particularly laminin-5 and especially laminin-5 subunit ⁇ , being produced, with the result, for example, of the decline in skin elasticity in human skin that occurs with increasing age. can be reduced.
  • the cosmetic use of the cosmetic or dermatological preparation according to the invention leads to the reduced formation of
  • compositions the appearance, vitality and health of cells and tissues. Specifically, it is described on page 89 in Example 11 that an extract of salmon eggs can promote wound healing. However, neither the fish extracts according to the invention nor a specific effect on the padding of the skin or the increased incorporation of triglycerides into adipocytes are described.
  • WO 2009136291 A2 also discloses production methods for extracts from fish eggs. The description of these methods is identical to those of WO
  • Example 13 the preparation of an extract from salmon and
  • Example 5 Furthermore, the same production method for fish spawn extracts is disclosed in document WO 201 1 138687 A2 on page 28, as in WO 2008020329 A2.
  • the extraction from salmon eggs described in Example 5 is also based on first washing the eggs. This is followed by a suspension in an aqueous lysis buffer and a homogenization.
  • the production methods differ from the present invention.
  • aqueous fish extract (I) and the lipophilic fish extract (II) in independent processes.
  • This makes it possible, for example, for an inventive aqueous fish extract from spoilers to be present together with a lipophilic fish extract of salmon eggs according to the invention in the preparation according to the invention. That is, in the following disclosure, the expression "both for the production of the aqueous fish extract (I) and for the production of the lipophilic fish extract (II)" is used, it refers to the one
  • aqueous fish extract (I) according to the invention and the lipophilic fish extract (II) according to the invention characterized in that the fish eggs are suspended in an extraction mixture containing an oil phase and an aqueous phase, the resulting suspension mixture is homogenized, and from this homogenate the aqueous phase to obtain the aqueous Fish Extract (I) is extracted and the oil phase of the homogenate is extracted to obtain the lipophilic fish extract (II).
  • aqueous fish extract (I) or of the lipophilic fish extracts (II) are preferred, and that the selection of fish eggs, process steps or parameters for a production process of the inventive aqueous
  • the fish eggs are suspended in an extraction mixture containing an oil phase and an aqueous phase, the resulting suspension mixture is homogenized, and from this homogenate the aqueous phase for obtaining the aqueous fish extract is extracted and the oil phase of the homogenate extracted to obtain the lipophilic fish extract is, are preferred or advantageous.
  • aqueous and lipophilic fish extracts according to the invention are prepared together as described above in a preparation process, this has the advantage that both the oil phase and the aqueous phase can be used for the preparation of the extracts according to the invention after the homogenization. This is off economical and ecological point of view, since less resources must be used and the waste products can be reduced.
  • a preferred subject of the present invention is a cosmetic or dermatological preparation comprising an aqueous fish extract and a lipophilic fish extract characterized in that the aqueous
  • eggs of different fish species can be used both for the preparation of the aqueous fish extract (I) and for the production of the lipophilic fish extract (II).
  • Preferred fish eggs are for the production of the aqueous fish extract
  • the lipophilic fish extract (II) selected from salmon, trout and sturgeon fish eggs. Particularly advantageous results are achieved in the preparation of the aqueous fish extract (I) and / or the lipophilic fish extract (II) in the use of spoilage. Accordingly, eggs of sturgeons are produced both for the production of the aqueous fish extract (I) and for the production of the lipophilic fish extract
  • the eggs can be used in principle according to the invention in the production processes of the invention.
  • the Siberian sturgeon, the short-nosed sturgeon, the Yangtze sturgeon, the sea sturgeon, the Russian sturgeon or Waxdick, the green sturgeon, the Sakhalin sturgeon, the Adriatic sturgeon, the plain sturgeon, the Atlantic sturgeon, are known among others Persian sturgeon, the Sterlet, the Amur sturgeon, the Chinese sturgeon, the Sternhausen, the European sturgeon, the white sturgeon, the Kaluga house and the European house, which is often referred to as beluga sturgeon. It should be noted here that a variety of sturgeon species are threatened with extinction, so that should be dispensed with the use of these.
  • aqueous fish extract (I) and / or the lipophilic fish extract (II) are each prepared within 24 hours after removal of the fish eggs.
  • the fish eggs are also preserved after removal with Borax.
  • the cryoprotectant consists of 1, 5M 1, 2-propanediol, 0.2M sucrose and water.
  • Use of the cryoprotectant prevents damage to the egg membrane during freezing and thawing.
  • the freeze-drying should take place at a rate of -1 ° C per minute up to a storage temperature of -80 ° C. Thawing the eggs before making the
  • Fish extract should be kept on ice until the eggs reach a temperature of 1 ° C to 5 ° C.
  • the preparation of the aqueous fish extract (I) according to the invention and / or the lipophilic fish extract (II) is carried out in this case after thawing the fish eggs to 1 ° C to 5 ° C.
  • the respective fish eggs are suspended in an extraction mixture containing an oil phase and an aqueous phase, so that a mixture of the fish eggs, the oil phase and the aqueous phase is obtained.
  • This mixture is referred to in both cases as a suspension mixture.
  • the oil phase contained in the extraction mixture advantageously comprises at least one oil which is liquid at 20 ° C. both for the preparation of the aqueous fish extract (I) and for the preparation of the lipophilic fish extract (II).
  • oil Caprylic / Capric triglycerides has been found because these ingredients are not expected in the spawners. It is furthermore advantageous both for the preparation of the aqueous fish extract (I) and for the preparation of the lipophilic fish extract (II) if the proportion of the oil
  • Caprylic / capric triglycerides in the oil phase of the extraction mixture at least 80 wt .-%, preferably at least 90 wt .-% and particularly preferably at least 97 wt .-%, based on the total weight of the oil phase of the extraction mixture.
  • Extraction mixture containing oil phase contains at least one antioxidant.
  • Tocopherol and / or BHT are preferably used as antioxidants both for the production of the aqueous fish extract (I) and for the preparation of the lipophilic fish extract (II), the total amount of which in the oil phase of the
  • Extraction mixture 0, 1 to 0.5 wt .-%, based on the total weight of the oil phase of the extraction mixture is.
  • the aqueous phase contained in the extraction mixture for the preparation of the aqueous fish extract (I) and / or for the preparation of the lipophilic fish extract (II) is advantageously a phosphate buffer, preferably containing 50 mM to 200 mM phosphates (for example from sodium hydrogenphosphate) and 0 , 1 to 0.3 wt .-% EDTA, based on the total weight of the respective aqueous phase of the extraction mixture for the preparation of the aqueous fish extract (I) and / or for the preparation of the lipophilic fish extract (II).
  • a phosphate buffer preferably containing 50 mM to 200 mM phosphates (for example from sodium hydrogenphosphate) and 0 , 1 to 0.3 wt .-% EDTA, based on the total weight of the respective aqueous phase of the extraction mixture for the preparation of the aqueous fish extract (I) and / or for the preparation of the lipophilic fish extract (II).
  • the aqueous phase of the extraction mixture according to the invention contains at least one preservative to prevent the growth of bacteria before, during and after the To prevent homogenization.
  • the aqueous fish extract (I) and for the production of the lipophilic fish extract (II) are advantageous both for the preparation of the aqueous fish extract (I) and for the preparation of the lipophilic fish extract (II)
  • Preservatives to be used are selected from the group phenoxyethanol,
  • the total amount of preservatives, in particular the total proportion of preservatives designated as preferred, in the aqueous phase of the extraction mixture is 0.5 to 3 wt .-%, based on the total weight of the aqueous phase of the extraction mixture.
  • a suspension mixture which according to the invention for the production of the aqueous fish extract (I) as well as for the production of the lipophilic fish extract (II) is referred to as a suspension mixture.
  • a suspension mixture it is advantageous both for the preparation of the aqueous fish extract (I) and for the preparation of the lipophilic fish extract (II) if the proportion by weight of the fish eggs in relation to the aqueous phase of the respective suspension mixture (a1) and / or a2)) 1: 2 to 2: 1, preferably 1: 1, 2 to 1, 2: 1.
  • Suspension mixture (a1) and or a2)) is 1: 0.2 to 1: 0.4.
  • the homogenization of the fish eggs in the suspension mixture described above from the eggs itself, the oil phase and the aqueous phase both for the preparation of the aqueous fish extract (I) and for the preparation of the lipophilic fish extract (II), the homogenization of the fish eggs in the suspension mixture described above from the eggs itself, the oil phase and the aqueous phase.
  • homogenization means processes in which cells are destroyed in order to access their contents - organelles, proteins, DNA, RNA or other biomolecules.
  • Non-mechanical and non-mechanical digestion methods can be used both for the preparation of the aqueous fish extract (I) and for the preparation of the lipophilic fish extract (II) for the homogenization.
  • Non-mechanical and non-mechanical digestion methods can be used both for the preparation of the aqueous fish extract (I) and for the preparation of the lipophilic fish extract (II) for the homogenization.
  • Digestion methods correspond for example to a chemical degradation of a cell wall.
  • the mechanical digestion methods are preferred according to the invention. These include, inter alia, the Dounce method, in which the cells are destroyed by shear forces, sonication, the cells through
  • Cavitation forces are shattered or digestions under exertion of mechanical pressure, for example, in which a sample is forced under pressure through a tight valve (Manton-Gaulin homogenizer). Since it can come to different homogenates depending on the homogenization, it is particularly preferred according to the invention Homogenisations vide under exertion of mechanical pressure
  • the extraction of the aqueous phase for the preparation of the aqueous fish extract (I) and the extraction of the oil phase for the production of the lipophilic fish extract (II) from the homogenates of the respective suspension mixture by centrifugation with subsequent phase separation so be after the
  • centrifugation it is advantageous for the preparation of the aqueous fish extract (I) as well as for the production of the lipophilic fish extract (II) when it is carried out at 1500 to 3000 G.
  • the centrifugation time is advantageously 30 minutes to 2 hours both for the production of the aqueous fish extract (I) and for the preparation of the lipophilic fish extract (II). Subsequently, it should be advantageously maintained until the phases have clearly separated. If the conditions identified above as being advantageous, a particularly clean separation of the components is possible.
  • aqueous fish extract (I) which are advantageous according to the invention continue to be present.
  • DNA constituents are present in a weight fraction of 0.02 to 0.1% by weight, proteins in a weight fraction of 5 to 15% by weight and carbohydrates in a weight fraction of 0.5 to 1% by weight. , based on the total weight of the aqueous fish extract (I).
  • aqueous fish extract (I) is so gentle that in addition the vitamins B2, B5 and vitamin PP can be extracted from the spawners.
  • the use of other extraction methods known in the art often leads to the loss or a considerable reduction of the abovementioned
  • Vitamin ingredients can now cosmetic or dermatological Preparations which contain a particularly vitamin-rich aqueous
  • the aqueous fish extract (I) obtained by the process according to the invention in a total proportion of 0.0001 to 10 wt .-%, preferably 0.05 to 5 wt .-% and in particular preferably 0.1 to 2 wt .-%, based on the total weight of the cosmetic or dermatological preparation, is contained in the cosmetic or dermatological preparation.
  • the cosmetic or dermatological preparation comprises an aqueous fish extract of spoilage received by the process according to the invention, in a total proportion of 0.0001 to 10 wt .-%, preferably 0.05 to 5 wt. % and particularly preferably 0, 1 to 2 wt .-%, based on the total weight of the cosmetic or dermatological
  • the obtained inventive aqueous fish extract (I) can be stabilized by this before incorporation into the cosmetic or dermatological preparation in a weight ratio of 1: 0.5 to 1: 1, 5 with an aqueous glycine solution containing 1 to 2 Wt .-% glycine, based on the total weight of the aqueous glycine solution is diluted.
  • the weight ratio refers to the aqueous fish extract (I) in relation to the aqueous glycine solution.
  • the use of the aqueous glycine solution causes stabilization of the proteins in the obtained aqueous fish extract (I), so that its durability is increased.
  • emulsifier with an HLB value in the range of 8 to 12.
  • HLB value in the range of 8 to 12.
  • Weight fraction of this emulsifier in the aqueous glycine solution is preferably 0.5 to 2 wt .-%, based on the total weight of the aqueous glycine solution.
  • Polysorbate 80 is particularly preferably chosen as the emulsifier.
  • the aqueous glycine solution is additionally characterized in that it contains at least one preservative selected from the group ethylhexylglycerol, phenoxyethanol and / or phenethyl alcohol. Particularly advantageous is the total weight fraction of the above-mentioned preservatives 0.5 to 3% by weight, based on the total weight of the glycine solution.
  • Such glycine solutions according to the invention make it possible to dispense with heating for bacterial reduction of the aqueous fish extract (I) according to the invention. By using the glycine solution according to the invention, contamination of the aqueous fish extract (I) with bacteria is excluded or reduced.
  • the aqueous glycine solution is advantageously characterized in that it contains at least one electrolyte, preferably sodium chloride, in a total proportion of 0.5 to 2% by weight, based on the total weight of the glycine solution.
  • the solution obtained from the aqueous fish extract (I) according to the invention and the aqueous glycine solution according to the invention advantageously has a pH in the range of 5.0 to 7.5, preferably 6.0 to 7.0, so that the constituents contained not by be degraded to acidic or basic conditions.
  • the resulting product from the aqueous fish extract (I) and the aqueous glycine solution can be stored without any disadvantages for up to one year in the dark with exclusion of light at 25 ° C before incorporation into a cosmetic or dermatological preparation.
  • the resulting aqueous fish extract (I) can be incorporated either directly or advantageously after addition of the aqueous glycine solution described in a variety of cosmetic or dermatological preparations.
  • the fatty acids include all unbranched, saturated and
  • the lipophilic fish extract (II) according to the invention is characterized in that the weight proportion of the polyunsaturated fatty acids in the lipophilic fish extract (II) is 30 to 40% by weight, based on the total weight of all the fatty acids contained in the lipophilic fish extract (II).
  • the proportion by weight of the omega-3 fatty acids in the lipophilic fish extract (II) is 15 to 25% by weight, based on the total weight of all fatty acids contained in the lipophilic fish extract (II).
  • advantageous lipophilic fish extracts according to the invention (II) are characterized in that the weight fraction of omega-6 fatty acids in the lipophilic fish extract (II) is 10 to 20 wt .-%, based on the total weight of all fatty acids contained in the lipophilic fish extract (II).
  • the stability, the shelf life and / or the purity of the lipophilic fish extract (II) according to the invention can be increased when the extracted oil phase of the homogenate is dried.
  • the drying with the appropriate to salts may be carried out with particular advantage with disodium phosphate (Na 2 SE 4).
  • the stability, the stability and / or the purity of the lipophilic fish extract (II) according to the invention can be increased by filtering the extracted oil phase.
  • the filtration is advantageously carried out so that the entire drying agent, for example disodium sulfate, is removed from the oil phase.
  • advantageous lipophilic fish extracts (II) are characterized in that they contain at least one preservative selected from the group consisting of phenoxyethanol, phenethyl alcohol and ethylhexylglycerol.
  • the total amount of preservatives in particular the
  • the lipophilic fish extract (II) has a resistance to bacterial attack of at least 2 years.
  • Demenschend is no immediate training in a cosmetic or dermatological preparation longer necessary.
  • the lipophilic fish extract (II) according to the invention is advantageously characterized in that the proportion by weight of triglycerides, in particular the proportion of decanoyl and octanoylglycerides (caprylic / capric triglycerides), 50 to 60 wt .-% based on the total weight of the lipophilic fish extract ( II).
  • the lipophilic fish extract (II), obtained by the process according to the invention in a total proportion of 0.001 to 10 Wt .-%, preferably 0.02 to 5 wt .-%, based on the total weight of the cosmetic or dermatological preparation, in the cosmetic or dermatological preparation according to the invention is contained.
  • the cosmetic or dermatological preparation comprises a lipophilic fish extract (II) of spoilage strains, obtained by the process according to the invention, in a total amount of 0.001 to 10 wt .-%, preferably 0.02 to 5 wt. %, based on the total weight of the cosmetic or dermatological preparation.
  • II lipophilic fish extract
  • the weight ratio of the aqueous fish extract (I) to the lipophilic fish extract (II) is from 100: 1 to 1: 100, preferably from 20: 1 to 1: 1, the total content of both fish extracts in the cosmetic or dermatological preparation of 0.001 to 10 wt .-%, preferably from 0.005 to 1 wt .-%, based on the total weight of the cosmetic or dermatological preparation.
  • the cosmetic or dermatological preparations according to the invention can be used in the usual cosmetic and / or dermatological pharmaceutical preparation forms, preferably as gel, O / W emulsion, W / O emulsion, W / O / W emulsion, O / W / O emulsion, Microemulsion, cosmetic stick present.
  • the cosmetic or dermatological preparations according to the invention may be present, preferably as emulsion, ointment, foundation, toner, aqueous solution, cream, gel, powder, mask, foam preparation and aerosol preparation.
  • Emulsions are generally understood to mean heterogeneous systems which consist of two liquids which are immiscible or only limitedly miscible, one of the two liquids being dispersed in the form of very fine droplets in the other liquid. With the naked eye, an emulsion appears as homogeneous. If both liquids are water and oil, and the oil is present as finely distributed droplets in the water, then it is an oil-in-water emulsion (O / W emulsion). On the other hand, if the water is present as finely distributed droplets in the oil, then it is a water-in-oil emulsion (W / O emulsion).
  • the cosmetic or dermatological preparation in which the fish extracts according to the invention are present is in the form of an O / W emulsion.
  • Emulsifiers serve to stabilize emulsions. Stabilization means in this
  • Demenschend can be determined by the use of appropriately selected
  • Emulsifier systems produce stable emulsions.
  • Emulsifiers are molecules with a polar, hydrophilic structural element and a nonpolar, lipophilic structural element. In general, such molecules can be defined by the HLB value (dimensionless number between 0 and 20) which indicates whether a preferred water or oil solubility is present. Water in oil Emulsifiers (W / O emulsifiers) usually have an HLB value in the range of 3 to 8.
  • W / O emulsifiers promote the stabilization of an aqueous phase suspended in an oil phase.
  • Oil-in-water emulsifiers (O / W emulsifiers) have an HLB value greater than 8 to 18. These promote the stabilization of an oil phase which is suspended in an aqueous phase.
  • the cosmetic or dermatological preparation containing the aqueous fish extract according to the invention and the lipophilic fish extract according to the invention is present as an oil-in-water emulsion, it is advantageous if the cosmetic or dermatological preparation contains at least one O / W emulsifier with an HLB Value in the range of greater 8 to 18 contains.
  • O / W emulsifiers are, for example, the following list:
  • such an O / W emulsion may advantageously also comprise W / O emulsifiers, the ratio of the O / W emulsifiers to the W / O emulsifiers, taking into account the respective HLB values, to be selected such that an O / W emulsion sets.
  • W / O emulsifiers the ratio of the O / W emulsifiers to the W / O emulsifiers, taking into account the respective HLB values, to be selected such that an O / W emulsion sets.
  • a known mixture of O / W emulsifiers and W / O emulsifiers is the commercial product Arlacel 170 from Croda containing glyceryl stearates and PEG-100 stearates, wherein the ratio of the two substances is chosen so that a total HLB of about 1 1 results.
  • the cosmetic or dermatological preparation according to the invention advantageously contains, in addition to the aqueous fish extract according to the invention and the lipophilic fish extract according to the invention, oils selected from the group of the lecithins and the
  • Fatty acid triglycerides namely the triglycerol esters of saturated and / or unsaturated, branched and / or unbranched alkanecarboxylic acids having a chain length of 8 to 24, in particular 12 to 18, carbon atoms.
  • the fatty acid triglycerides can be advantageously selected from the group of synthetic, semi-synthetic and natural oils, such as e.g. Olive oil, sunflower oil, soybean oil, peanut oil, rapeseed oil, almond oil, palm oil, coconut oil, castor oil, wheat germ oil, grapeseed oil, thistle oil, evening primrose oil, macadamia nut oil, and the like.
  • the cosmetic or dermatological preparation according to the invention may advantageously contain oils which are selected from the group of branched and unbranched hydrocarbons and waxes, in particular Vaseline (petrolatum), paraffin oil, squalane and squalene, polyolefins and hydrogenated polyisobutenes.
  • oils which are selected from the group of branched and unbranched hydrocarbons and waxes, in particular Vaseline (petrolatum), paraffin oil, squalane and squalene, polyolefins and hydrogenated polyisobutenes.
  • polyolefins polydecenes are the preferred substances.
  • the cosmetic or dermatological preparation according to the invention may advantageously contain fat and / or wax components from the group of vegetable waxes, animal waxes, mineral waxes and petrochemical waxes.
  • fat and / or wax components from the group of vegetable waxes, animal waxes, mineral waxes and petrochemical waxes.
  • Favorable according to the invention are candelilla wax, carnauba wax, Japan wax,
  • fat and / or wax components are chemically modified waxes and synthetic waxes, such as those available under the trade names Syncrowax HRC (glyceryl tribehenate), and Syncrowax AW 1 C (C18-36 fatty acid) from CRODA GmbH, and montan ester waxes, Sasol waxes, hydrogenated
  • Jojoba waxes synthetic or modified beeswaxes (eg dimethicone copolyol beeswax and / or C30-50 alkyl beeswax), polyalkylene waxes,
  • Polyethylene glycol waxes but also chemically modified fats such.
  • Hydrogenated vegetable oils for example hydrogenated castor oil and / or hydrogenated coconut fat glycerides
  • triglycerides such as trihydroxystearin, fatty acids, fatty acid esters and
  • Glycol esters such as C20-40 alkyl stearate, C20-40 alkyl hydroxystearoyl stearate and / or glycol montanate.
  • the cosmetic or dermatological preparation contains cyclic, branched and / or linear silicones.
  • the group of cyclic, branched and / or linear silicones are also referred to in the present disclosure as "silicone oils.”
  • Linear silicone oils are described by the I NCI designation Dimethicone and have a structure according to the formula (I)
  • Cyclic silicones are known by the INCI name Cyclomethicone.
  • the proportion by weight of the silicone oils in the cosmetic or dermatological preparation is from 3% by weight to 10% by weight, based on the total weight of the cosmetic or dermatological preparation.
  • the cosmetic or dermatological preparation is advantageous thereby
  • the total proportion of the oil phase in the O / W emulsion is from 2 to 30% by weight, preferably from 5% by weight to 25% by weight and particularly preferably from 8% by weight to 22% by weight to the total weight of the cosmetic or dermatological preparation, wherein the lipophilic fish extract according to the invention is contained in the oil phase.
  • the silicone oils also belong to the oil phase of the cosmetic or dermatological preparation.
  • the cosmetic or dermatological preparation contains one or more rheology modifiers.
  • Preferred rheology modifiers to be selected are selected from the group of the following INCI substances:
  • Carbomer (Carbopols of the types 980, 981, 2984, 5984 from the company Lubrizol);
  • Acrylates copolymer eg Carbopol® Aqua SF-1 polymer from the company Lubrizol
  • acrylates / C 10-30 alkyl acrylate crosspolymer eg Pemulen TR 1, Pemulen TR 2, Carbopol 1328 from the company Lubrizol
  • Ammonium Acryloyl Dimethyl Taurate / VP Copolymer eg
  • polyacrylate-1 crosspolymer e.g., Carbopol® Aqua CC Polymer from Lubrizol
  • Sodium polyacrylates e.g., Cosmedia SP from BASF
  • Celluloses and cellulose derivatives e.g. hydroxypropyl methylcellulose
  • Methylcellulose, carboxymethylcellulose, hydroxyethylcellulose, hyaluronic acid and xanthan gum Methylcellulose, carboxymethylcellulose, hydroxyethylcellulose, hyaluronic acid and xanthan gum
  • Starches for example tapioca starch.
  • the rheology modifiers are particularly preferably selected from the group of the substances known by the INCI name carbomer, acrylates / C 10-30 alkyl acrylates Crosspolymer, sodium polyacrylate, hydroxyethyl acrylate / sodium acryloyl dimethyl taurate copolymer and ammonium acryloyl dimethyl taurate / VP copolymer.
  • Total content of the rheology modifiers characterized above as preferred 0.05 to 5 wt .-%, preferably from 0, 1 to 2.5 wt .-%, based on the total weight of the cosmetic or dermatological preparation.
  • Total weight of the cosmetic or dermatological preparation is included.
  • rheology modifier according to the invention to the oil phase contained 1: 1 to 1: 30, preferably 1: 2 to 1: 28, particularly preferably 1: 20 to 1: 27.
  • cosmetic or dermatological preparations according to the invention have a surprisingly advantageous creaminess and are not perceived as crumbly or too oily and too liquid by the consumer.
  • inventive cosmetic or dermatological preparation cetyl alcohol, stearyl alcohol or a mixture of
  • Cetyl alcohol and stearyl alcohol contains.
  • the cosmetic or dermatological preparation contains cetyl alcohol, stearyl alcohol or a mixture of cetyl alcohol and stearyl alcohol, it is advantageous according to the invention if the total proportion of these substances is from 0.5 to 5.5% by weight, based on the total weight of the cosmetic or dermatological preparation , is.
  • dermatological preparation additionally contains one or more substances selected from the group ethanol, isopropanol, propylene glycol, propanediol, glycerol, ethylene glycol, ethylene glycol monoethyl or monobutyl ether, propylene glycol monomethyl, monoethyl or monobutyl ether and / or diethylene glycol monomethyl or monoethyl ether. It is preferred if the cosmetic or dermatological preparation contains glycerol and / or propanediol.
  • the cosmetic or dermatological preparations according to the invention preferably contain at least one UV-A, UV-B and / or broad-spectrum filter substance.
  • the formulations may, although not necessary, optionally also contain one or more organic and / or inorganic pigments as UV filter substances, which may be present in the water and / or the oil phase.
  • the preparations according to the present invention may contain at least one
  • Room temperature liquid UV filter substance included.
  • Preferred inorganic pigments are metal oxides and / or other sparingly water-soluble or insoluble metal compounds, in particular oxides of titanium (T1O2), zinc (ZnO), iron (eg Fe20s), zirconium (ZrO2), silicon (S1O2), manganese ( eg MnO), aluminum (Al 2 O 3), cerium (for example Ce 2 O 3), mixed oxides of the corresponding metals and mixtures of such oxides as well as the barium sulfate (BaSO 4 ).
  • the pigments can also be used advantageously in the form of commercially available oily or aqueous predispersions.
  • dispersants and / or solubilizers can be added to these predispersions.
  • the pigments may advantageously be surface-treated ("coated"), in which case a hydrophilic, amphiphilic or hydrophobic character is to be formed or retained, for example or hydrophobic inorganic and / or organic layer
  • a hydrophilic, amphiphilic or hydrophobic character is to be formed or retained, for example or hydrophobic inorganic and / or organic layer
  • the various surface coatings may also contain water for the purposes of the present invention.
  • Suitable titanium dioxide particles and predispersions of titanium dioxide particles are available from the following companies under the following trade names:
  • UV-A filter substances for the purposes of the present invention are dibenzoyl methane derivatives, in particular 4- (tert-butyl) -4'-methoxydibenzoylmethane (CAS No. 70356-09-1), which has been sold by Givaudan under the trademark Parsol ® 1789 and sold by Merck under the trade name Eusolex® 9020.
  • Salts of 2-phenylbenzimidazole-5-sulfonic acid such as its sodium, potassium or triethanolammonium salt, and the sulfonic acid itself with the INCI name phenylbenzimidazole sulfonic acid (CAS No. 27503-81-7), which is available, for example, under the trade name Eusolex 232 from Merck or under Neo Heliopan Hydro from Symrise;
  • Benzene-1, 4-di (2-oxo-3-bornylidenemethyl-10-sulfonic acid) has the INCI name Terephtalidene Dicampher sulfonic acid (CAS. No .: 90457-82-2) and is, for example, under the trade name Mexoryl SX of available from Chimex; Sulfonic acid derivatives of 3-Benzylidencamphers, such as.
  • Benzoxazole derivatives such as.
  • Hydroxybenzophenones e.g. B. 2- (4'-diethylamino-2'-hydroxybenzoyl) -benzoeklare- hexyl ester (also: aminobenzophenone), which is available under the trade name Uvinul A Plus in the company. BASF.
  • Triazine derivatives such as. B. 2,4-bis - ⁇ [4- (2-ethyl-hexyloxy) -2-hydroxy] -phenyl ⁇ -6- (4-methoxyphenyl) -1, 3,5-triazine (INCI: Bis- Ethylhexyloxylphenol methoxyphenyl triazine), which is available under the trade name Tinosorb® S from CIBA-Chemikalien GmbH; Dioctylbutylamidotriazone (INCI: Diethylhexyl Butamido Triazone), which is available under the trade name UVASORB HEB from Sigma 3V; 4,4 ', 4 "- (1,3,5-triazine-2,4,6-triyltriimino) -tris-benzoic acid tris (2-ethylhexyl ester), also: 2,4,6-tris [anilino- (p-carbo-2'-ethyl-1'-
  • Benzotriazoles such as. B. 2,2'-methylene-bis (6- (2H-benzotriazol-2-yl) -4- (1,1,3,3-tetramethylbutyl) -phenol) (INCI: Methylene bis-benztriazolyl tetramethylbutylphenol ), which z. B. under the trade name Tinosorb® M at CIBA-Chemikalien GmbH is available.
  • 3-benzylidene camphor derivatives preferably 3- (4-methylbenzylidene) camphor, 3-benzylidene camphor;
  • 4-aminobenzoic acid derivatives preferably (2-ethylhexyl) 4- (dimethylamino) benzoate, 4- (dimethylamino) benzoic acid amyl ester;
  • Esters of benzalmalonic acid preferably di (2-ethylhexyl) 4-methoxybenzalmalonate
  • Esters of cinnamic acid preferably 4-methoxycinnamic acid (2-ethylhexyl) ester, 4-methoxycinnamic acid isopentyl ester;
  • benzophenone preferably 2-hydroxy-4-methoxybenzophenone, 2-hydroxy-4-methoxy-4'-methylbenzophenone, 2,2'-dihydroxy-4-methoxybenzophenone and
  • Ethylhexyl 2-cyano-3,3-diphenylacrylate (Octocrylene), which is available from BASF under the name Uvinul® N 539 T.
  • Particularly advantageous cosmetic or dermatological preparations in the sense of the present invention which are distinguished by a high or very high UV-A protection, preferably contain further UV-A and / or broadband filters in addition to the filter substance (s) according to the invention.
  • dibenzoylmethane derivatives for example 4- (tert-butyl) -4'-methoxydibenzoylmethane] and / or 2,4-bis - ⁇ [4- (2-ethyl-hexyloxy) -2-hydroxy] -phenyl ⁇ -6- (4-methoxyphenyl) -1, 3,5-triazine and / or phenylene-1,4-bis (2-benzimidazyl) -3,3'-5,5'-tetrasulfonic acid bis-sodium salt each individually or in any combination with each other.
  • dibenzoylmethane derivatives for example 4- (tert-butyl) -4'-methoxydibenzoylmethane
  • UV filters which can be used in the context of the present invention is of course not intended to be limiting.
  • the total amount of the filter substances is from the range of 0.1 to 30 wt .-%, preferably 0.5 to 10 wt .-%, in particular 1, 0 to 8.0 wt .-% - each based on the total weight of the cosmetic or dermatological preparations - chosen to provide cosmetic or dermatological preparations which protect the hair or skin from the entire range of ultraviolet radiation.
  • the cosmetic or dermatological preparation according to the invention comprises at least one active ingredient for cosmetic treatment and / or
  • the cosmetic or dermatological preparation advantageously contains at least one alkylamidothiazole.
  • R 4 H, -Ci-C24-alkyl (linear and branched), -Ci-C24-alkenyl (linear and branched), -d-Ce- cycloalkyl, -d-C24-hydroxyalkyl (linear and branched), -Ci -C24-alkylaryl (linear and branched), -Ci-C24-alkylheteroaryl (linear and branched),
  • X ' -H, -Ci-C24-alkyl (linear and branched), -Ci-C24-alkenyl (linear and branched), -Ci-Ce- cycloalkyl, -Ci-C24-aryl (optionally mono- or polysubstituted with -OH, -F, -Cl, -Br, -I, - OMe, -NH2, -CN), -Ci-C24 heteroaryl (optionally mono- or polysubstituted with -OH, -F, -C1, -Br, -I, -OMe, -NH 2 , -CN), -Ci-C 2 4-alkylaryl (linear and branched), -Ci-C 2 4-Alkylheteroaryl (linear and branched), -aryl (if necessary.
  • Y ' H, -Ci-C24-alkyl (linear and branched), -Ci-C24-alkenyl (linear and branched), -Ci-Ce- cycloalkyl, -Ci-C24-aryl, -Ci-C24-heteroaryl, -Ci-C24-alkylaryl (linear and branched), -C1-C24-alkylheteroaryl (linear and branched), -aryl, -phenyl, -2,4-dihydroxyphenyl, -2,3-dihydroxyphenyl, -2,4-dimethoxyphenyl , -2,3-dimethoxyphenyl, -COO-alkyl, -COO-alkenyl, - COO-Cylcloalkyl, -COO-aryl, -COO-heteroaryl, and X ', Y' may optionally
  • the said thiazoles can be present both as free base and as salt: e.g. as fluoride, chloride, bromide, iodide, sulfate, carbonate, ascorbate, acetate or phosphate.
  • salt e.g. as fluoride, chloride, bromide, iodide, sulfate, carbonate, ascorbate, acetate or phosphate.
  • halogen salts e.g. Chloride and bromide.
  • X ' is selected from the group of substituted phenyls, where the substituents Z' can be selected from the group -H, -OH, -F, -Cl, -Br, -I, -OMe, -NH2, -CN , Acetyl and may be the same or different.
  • X ' is particularly advantageously selected from the group of phenyl groups substituted by one or more hydroxyl groups, where the substituent Z' can be selected from the group -H, -OH, -F, -Cl, -Br, -I, -OMe, -NH 2 , -CN, acetyl and the following generic structure is preferred in which Y ', R 3 and R 4 may have the properties defined above.
  • R 3 -C-C24-alkyl (linear and branched), -C-C24-alkenyl (linear and branched), -C-Ce-cycloalkyl, d-Ce-cycloalkyl-alkylhydroxy, -C1-C24 alkyl hydroxy (linear and branched), -C1-C24 alkylamine (linear and branched), -Ci-C24-alkylaryl (linear and branched), -Ci-C24-alkylaryl-alkyl-hydroxy (linear and branched), -Ci-C24- Alkylheteroaryl (linear and branched), -C1-C24-alkyl-0-Ci-C24-alkyl (linear and branched), -C1-C24 Alky-Morpholino, -C1-C24 Alky-Piperidino, -C1-C24 Alky-piperazin
  • R 4 H, -Ci-C24-alkyl (linear and branched).
  • Z ' -H, -OH, -F, -Cl, -Br, -I, -OMe, -NH 2 , -CN, acetyl.
  • R 3 -C-C24-alkyl (linear and branched), -C-C24-alkenyl (linear and branched), -C-Ce-cycloalkyl, d-Ce-cycloalkyl-alkylhydroxy, -C1-C24 alkyl hydroxy (linear and branched), -C1-C24 alkylamine (linear and branched), -Ci-C24-alkylaryl (linear and branched), -Ci-C24-alkylaryl-alkyl-hydroxy (linear and branched), -Ci-C24- Alkylheteroaryl (linear and branched), -C1-C24-alkyl-0-Ci-C24-alkyl (linear and branched), -C1-C24 Alky-Morpholino, -C1-C24 Alky-Piperidino, -C1-C24 Alky-piperazin
  • a i - (4- (2,4-dihydroxyphenyl) thiazol-2-yl) -2- (4- (hydroxymethyl) phenyl) acetamides are the preferred according to the invention.
  • Alkylamidothiazoles in the cosmetic or dermatological preparations according to the invention 0.000001 to 10 wt .-%, in particular 0.0001 to 3 wt .-%, most preferably 0.001 to 1 wt .-%, each based on the total weight of
  • the cosmetic or dermatological preparations may also contain further cosmetic auxiliaries, as is customary in such preparations for example, further bodying agents, film formers, stabilizers, fillers, preservatives, perfumes, foaming inhibitors, colorants, other pigments which have a coloring effect, surface-active substances, softening, moistening and / or moisturizing substances,
  • anti-inflammatory substances additional active ingredients such as vitamins or proteins, insect repellents, bactericides, virucides, salts, antimicrobial, proteolytic or keratolytic substances or other conventional ingredients of a cosmetic formulation such as other alcohols, polyols, foam stabilizers, organic solvents or electrolytes.
  • additional active ingredients such as vitamins or proteins, insect repellents, bactericides, virucides, salts, antimicrobial, proteolytic or keratolytic substances or other conventional ingredients of a cosmetic formulation such as other alcohols, polyols, foam stabilizers, organic solvents or electrolytes.
  • oil phase was prepared consisting of 99.98 wt .-%
  • Caprylic / capric triglycerides 0.01% by weight tocopherol and 0.01% by weight BHT.
  • the additionally provided aqueous phase consisted of:
  • the weight ratio of oil phase to fish eggs was 0.3: 1 and that
  • Weight ratio of the aqueous phase to the eggs was 1: 1.
  • the resulting mixture of oil phase, aqueous phase and fish eggs was then homogenized using a Manton-Gaulin homogenizer.
  • the homogenate obtained was then centrifuged at 2000 G for one hour. This was followed by manual phase separation, the water phase representing the aqueous fish extract (I) according to the invention.
  • aqueous fish extract (I) To improve the shelf life of the obtained aqueous fish extract (I), this was in the ratio 1: 1 with an aqueous glycine solution consisting of 1, 5 wt .-% glycine, 1, 5 wt .-% sodium chloride, 1, 5 wt .-% phenoxyethanol , 1, 0 wt .-% polysorbate 80 and water mixed. Subsequently, filtration was carried out to improve the purity.
  • aqueous fish extract solution from (a) The resulting mixture of aqueous fish extract (II) and glycine solution is referred to in the following example formulations aqueous fish extract solution from (a).
  • fish eggs from white sturgeon (only fish eggs from breeding stocks were used) were removed and mixed with borax. Within 24 hours after removal, the production of the lipophilic fish extract took place.
  • oil phase was prepared consisting of 99.98 wt .-%
  • Caprylic / capric triglycerides 0.01% by weight tocopherol and 0.01% by weight BHT.
  • the additionally provided aqueous phase consisted of:
  • the provided oil phase and the provided aqueous phase were combined and then the fish eggs were suspended in this mixture.
  • the weight ratio of the oil phase to the spawners was 0.3: 1 and the weight ratio of the aqueous phase to the spawners was 1: 1.
  • the resulting mixture of oil phase, aqueous phase and fish eggs was then homogenized using a Manton-Gaulin homogenizer.
  • the homogenate obtained was then centrifuged at 2000 G for one hour. This was followed by manual phase separation, the oil phase representing the lipophilic fish extract (II) according to the invention.
  • the lipophilic fish extract (II) obtained was dried with sodium sulfate and then filtered to improve the purity to remove the sodium sulfate and other insoluble matter.
  • Aqueous fish extract according to the invention (I) before addition of the glycine solution, has been able to determine the following constituents of the extract:
  • Carbohydrates 0.84% by weight
  • Vitamin B2 (riboflavin) 376 g / 100g
  • Vitamin B5 pantothenic acid
  • wt .-% information is based on the total weight of the water phase of the homogenate from (a), ie the aqueous fish extract (L) relate.
  • omega-3 fatty acids in the lipophilic fish extract (II) is 20.3% by weight, based on the total weight of all the fatty acids present.
  • omega-6 fatty acids in the lipophilic fish extract (II) is 14.8% by weight, based on the total weight of all the fatty acids present.
  • the proportion of phenoxyethanol is in the range of 0, 1 to 1, 5 wt .-% based on the total weight of the lipophilic fish extract (II).
  • Fish extract (II) In one procedure fish eggs were taken from the Siberian sturgeon (only fish eggs from breeding stocks were used) and borax was added. Within 24 hours after removal, the production of the aqueous fish extract (I) and of the lipophilic fish extract (II) took place.
  • oil phase was prepared consisting of 99.98 wt .-%
  • Caprylic / capric triglycerides 0.01% by weight tocopherol and 0.01% by weight BHT.
  • the additionally provided aqueous phase consisted of:
  • the provided oil phase and the provided aqueous phase were combined and then the fish eggs were suspended in this mixture.
  • the weight ratio of oil phase to fish eggs was 0.3: 1 and that
  • Weight ratio of the aqueous phase to the eggs was 1: 1.
  • the resulting mixture of oil phase, aqueous phase and fish eggs was then homogenized using a Manton-Gaulin homogenizer.
  • the homogenate obtained was then centrifuged at 2000 G for one hour. This was followed by manual phase separation, the aqueous phase representing the aqueous fish extract (I) according to the invention and the oil phase the lipophilic fish extract (II) according to the invention.
  • aqueous fish extract (I) was in the ratio 1: 1 with an aqueous glycine solution consisting of 1, 5 wt .-% glycine, 1, 5 wt .-% sodium chloride, 1, 5 wt .-% phenoxyethanol , 1, 0 wt .-%
  • aqueous fish extract solution e
  • Disodium phenyl dibenzimidazole tetrasulfonates 1.0 1.0 1.5 0.5 2.0
  • aqueous fish extract solution from (a). (50% 0.4 0.2 0.16 0.4 0.1 aqueous fish extract (I) + 50% glycine solution)
  • aqueous fish extract solution from (e). (50% 0.06 0.4 0, 12 0.35 0.25 aqueous fish extract + 50% glycine solution)
  • Glycerin 10 5.0 6.0 4.0 7.0
  • Additives (distarch phosphate, S1O2, talc, BHT 0.03 0.05 3.0 aluminum stearate)
  • aqueous fish extract solution from (a). (50% 0.2 0.1 0.3 0.09 0.4 aqueous fish extract + 50% glycine solution)
  • Titanium Dioxide 0.3 0.1 0.2

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Reproductive Health (AREA)
  • Cosmetics (AREA)

Abstract

L'invention concerne une préparation cosmétique ou dermatologique contenant un extrait d'oeuf de poisson aqueux et un extrait d'oeuf de poisson lipophile, capable de repulper la peau, d'augmenter le stockage de triglycérides dans des adipocytes, d'augmenter l'expression de la laminine, de préférence de la laminine-5 et de préférence encore de la sous-unité ß de la laminine-5 et/ou de maintenir l'élasticité et/ou l'extensibilité de la peau humaine.
EP18726089.8A 2017-05-22 2018-05-11 Préparation cosmétique ou dermatologique contenant un extrait d'oeuf de poisson aqueux et un extrait d'oeuf de poisson lipophile Withdrawn EP3630300A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH00668/17A CH713170B1 (de) 2017-05-22 2017-05-22 Kosmetische oder dermatologische Zubereitung, enthaltend einen wässrigen und einen lipophilen Fischeiextrakt.
PCT/EP2018/062193 WO2018215219A1 (fr) 2017-05-22 2018-05-11 Préparation cosmétique ou dermatologique contenant un extrait d'oeuf de poisson aqueux et un extrait d'oeuf de poisson lipophile

Publications (1)

Publication Number Publication Date
EP3630300A1 true EP3630300A1 (fr) 2020-04-08

Family

ID=62203040

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18726089.8A Withdrawn EP3630300A1 (fr) 2017-05-22 2018-05-11 Préparation cosmétique ou dermatologique contenant un extrait d'oeuf de poisson aqueux et un extrait d'oeuf de poisson lipophile

Country Status (7)

Country Link
US (1) US11491191B2 (fr)
EP (1) EP3630300A1 (fr)
JP (1) JP2020521006A (fr)
KR (1) KR102637659B1 (fr)
CN (1) CN110621381B (fr)
CH (1) CH713170B1 (fr)
WO (1) WO2018215219A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102297395B1 (ko) * 2019-03-19 2021-09-02 주식회사 선마린바이오테크 열빙어 알 또는 도루묵 알 추출물을 포함하는 화장료 조성물 및 그 추출물의 제조방법
KR102583992B1 (ko) * 2023-03-15 2023-10-05 이용광 철갑상어 수용성 오일을 함유하는 아토피 피부염 치료용 제제

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2096704A1 (fr) * 1970-06-17 1972-02-25 Millet Ingrid Produit cosmetique a base d'oeufs de poisson
WO2002092540A1 (fr) 2001-05-14 2002-11-21 Martek Biosciences Corporation Production et utilisation d'une fraction riche en lipide polaire contenant des acides gras hautement insatures omega 3 et/ou omega 6 de microbes, de semences genetiquement modifiees et d'organismes marins
DE10238450A1 (de) * 2002-08-22 2004-03-04 Beiersdorf Ag Zubereitung zur Behandlung von Fehlpigmentierungen der Haut
JP2005179340A (ja) 2003-11-26 2005-07-07 Asahi Kasei Chemicals Corp 脂質組成物の製造方法
WO2008020329A2 (fr) 2006-05-11 2008-02-21 Regenics As Administration de cellules et d'extraits cellulaires pour le rajeunissement
WO2009136291A2 (fr) 2008-05-09 2009-11-12 Regenics As Extraits cellulaires
WO2011138687A2 (fr) 2010-05-06 2011-11-10 Regenics As Utilisation d'extraits cellulaires pour le rajeunissement de la peau
GB201110783D0 (en) * 2011-06-24 2011-08-10 Aqua Bio Technology Asa Methods and uses
DE102011083259A1 (de) * 2011-09-23 2013-03-28 Beiersdorf Ag Alkylamidothiazole, deren kosmetische oder dermatologische Verwendung sowie kosmetische oder dermatologische Zubereitungen mit einem Gehalt an solchen Alkylamidothiazolen
PL2691069T3 (pl) * 2012-01-23 2017-03-31 Restorsea, Llc Kosmetyk
AU2013356930B2 (en) * 2012-12-10 2017-01-05 Regenics As Use of egg cellular extracts for skin rejuvenation
DE102013204081A1 (de) * 2013-03-11 2014-09-11 Beiersdorf Ag Wirkstoffkombinationen aus Alkylamidothiazolen und einen oder mehreren kosmetisch oder dermatologisch unbedenklichen Konservierungsmitteln
JP5916799B2 (ja) 2014-06-12 2016-05-11 株式会社アテナ チョウザメの卵からの抽出液
KR101670765B1 (ko) * 2014-09-19 2016-11-01 주식회사 명진뉴텍 글리신계 물질을 포함하는 방부조성물
WO2016143282A1 (fr) 2015-03-10 2016-09-15 株式会社デンソー Procédé de soudage de substrats
JP6573241B2 (ja) 2015-03-18 2019-09-11 株式会社Ihi 脂質組成物及びその製造方法
CN107375180B (zh) 2017-08-11 2020-10-16 北京斯利安药业有限公司 一种护肤品组合物、面膜及其制备方法

Also Published As

Publication number Publication date
KR20200007847A (ko) 2020-01-22
US11491191B2 (en) 2022-11-08
CN110621381A (zh) 2019-12-27
US20200188447A1 (en) 2020-06-18
CH713170B1 (de) 2018-05-31
CN110621381B (zh) 2024-06-18
WO2018215219A1 (fr) 2018-11-29
JP2020521006A (ja) 2020-07-16
KR102637659B1 (ko) 2024-02-15

Similar Documents

Publication Publication Date Title
EP1923045B1 (fr) Formule cosmétique à glucosyle glycérides et matières premières en poudre
EP1796619A1 (fr) Emulsion huile dans l'eau contenant des pigments filtrants de protection solaire anti-uv inorganiques et du sulfate d'alkyle
DE102004047286A1 (de) Kosmetische Lichtschutzzubereitung auf Basis von Mikropigmenten
DE102010038952A1 (de) Konservierungsmittel-Zusammensetzungen und Kosmetika enthaltend diese
DE102007005093A1 (de) Kosmetische Zubereitung gegen Hautpigmentierungen
EP3630300A1 (fr) Préparation cosmétique ou dermatologique contenant un extrait d'oeuf de poisson aqueux et un extrait d'oeuf de poisson lipophile
DE102006034531A1 (de) Kosmetische Zubereitung mit (2-Hydroxyethyl)harnstoff und Myristylmyristat
WO2019149509A1 (fr) Complexe de principes actifs pour préparations cosmétiques
US20230355507A1 (en) Use of caviar extracts
EP3630299A1 (fr) Préparation cosmétique ou dermatologique contenant un extrait d'oeuf de poisson
EP1889597A1 (fr) Combinaisons d'agents actifs à partir d'un composé ascorbyl-lécithine hydrogénée
EP1834630B1 (fr) Préparations cosmétiques ou dermatologiques contenant de la glycyrrhétine et/ou de la glycyrrhizine et de la 2,4-Bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phényl}-6-(4-methoxyphenyl)-1,3,5-triazine
WO2004014325A1 (fr) Preparations cosmetiques a deux phases
CH713171B1 (de) Kosmetische oder dermatologische Zubereitung, enthaltend einen wässrigen Fischeiextrakt.
EP4272724A1 (fr) Complexe de principes actifs pour préparations cosmétiques
EP3573594A1 (fr) Associations de principes actifs constituées de trans-4-t-butylcyclohexanol et d'un ou de plusieurs akylamidothiazols et préparations cosmétiques ou dermatologiques contenant ces associations de principes actifs
WO2006128779A1 (fr) Preparations cosmetiques presentant une certaine teneur en extrait aqueux d'anis et en agents emulsifiants non ioniques specifiques
DE102017200921A1 (de) Kosmetische oder dermatologische Zubereitungen mit einem Gehalt an sphärischen Silicapartikeln, welche mit Titandioxid und Eisenoxiden beschichtet sind und mittelkettigen aliphatischen Diolen
DE10225772A1 (de) Kosmetische oder dermatologische Formulierungen zur Pflege der Haut nach einem Sonnenbad oder einer Rasur
DE202006021305U1 (de) Kosmetische oder dermatologische Zubereitungen enthaltend Glycyrrhetin und/oder Glycyrrhizin und 2,4-Bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)- 1,3,5-triazin
DE202006021302U1 (de) Kosmetische oder dermatologische Zubereitungen enthaltend Glycyrrhetin und/oder Glycyrrhizin und 2,4-Bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)- 1,3,5-triazin
DE102007032663A1 (de) Kosmetische oder dermatologische Zubereitungen enthaltend ein oder mehrere Apiogalacturonane oder einen oder mehrere Apiogalacturonane enthaltenden Extrakt aus Zostera marina und eine oder mehrere UV-Licht absorbierende Substanzen
DE202006021297U1 (de) Kosmetische oder dermatologische Zubereitungen enthaltend Glycyrrhetin und/oder Glycyrrhizin und 2,4-Bis-{[4-(2-ethyl-hexyloxy)-2-hydroxy]-phenyl}-6-(4-methoxyphenyl)-1,3,5-triazin

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200102

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20210813

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20211224